Analyzing Mateon Therapeutics (OTCMKTS:MATN) & Indivior (OTCMKTS:INVVY)

Volatility & Risk

Indivior has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Mateon Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Valuation and Earnings

This table compares Indivior and Mateon Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$791.00 million	3.81	$205.00 million	$1.05	20.81
Mateon Therapeutics	N/A	N/A	-$6.64 million	($0.02)	-4.70

Indivior has higher revenue and earnings than Mateon Therapeutics. Mateon Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

0.1% of Indivior shares are owned by institutional investors. Comparatively, 0.1% of Mateon Therapeutics shares are owned by institutional investors. 39.2% of Mateon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Indivior and Mateon Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Indivior	N/A	N/A	N/A
Mateon Therapeutics	N/A	-64.66%	-42.92%

Summary

Indivior beats Mateon Therapeutics on 6 of the 9 factors compared between the two stocks.

About Indivior

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

About Mateon Therapeutics

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.